Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy and Safety of Dapagliflozin as Monotherapy Compared With Acarbose in Drug-Naive Patients With Type 2 Diabetes Mellitus (T2DM) in China

NCT03344341 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03344341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03344341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy and Safety of Dapagliflozin as Monotherapy Compared With Acarbose in Drug-Naive Patients With Type 2 Diabetes Mellitus (T2DM) in China
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Terminated
Start date
December 15, 2017
Completion date
May 24, 2019
Enrollment
304 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus